Weak nausea drug data knocks back Tesaro shares | (Reuters) - Tesaro Inc's experimental drug for treating chemotherapy-induced nausea and vomiting (CINV) failed to show enough benefit in trials to give it an edge over competing drugs, sending its shares down as much as 24 percent. | | | | | | Analysis: How the White House is rebranding Obamacare for 'young invincibles' | WASHINGTON (Reuters) - Last summer, White House officials planning a nationwide push to urge young adults to enroll in new health insurance plans had a big problem: Polls showed that many young, healthy people who could be key to the success of the Affordable Care Act knew little about it or its October 1 rollout. | | | | French implant firm Carmat could seek investors: co-founder | PARIS (Reuters) - France's Carmat, developer of an artificial heart implanted into its first patient last week, may seek an injection of funds from fresh investors to help tap a potential multi-billion-euro global market, a senior executive said. | | | | Past sperm and egg donors split on losing anonymity | NEW YORK (Reuters Health) - People who donated sperm and eggs before 1998 in one Australian state were able to remain anonymous, but potential new laws could have changed that. A recent study found those donors were split on the idea of possible contact from their donor children. | | | | | | | The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today | | | | | | | A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today | | | | | » MORE NEWSLETTERS | |
No comments:
Post a Comment